Listar por autor "Godoy-Ortiz, Ana"
Mostrando ítems 1-3 de 3
-
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
Godoy-Ortiz, Ana; Sánchez-Muñoz, Alfonso
; Chica Parrado, María del Rosario; Álvarez-Pérez, Martína; Ribelles, Nuria; Rueda-Domínguez, Antonio; Alba-Conejo, Emilio[et al.] (Frontiers Media, 2019)
The main obstacle for designing effective treatment approaches in breast cancer is the extensive and the characteristic heterogeneity of this tumor. The vast majority of critical genomic changes occurs during breast cancer ... -
Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis
Jiménez-Rodríguez, Begoña; Alba-Bernal, Alfonso; López-López, Esperanza; Quirós-Ortega, María Elena; Carbajosa, Guillermo; Garrido-Aranda, Alicia; Álvarez-Pérez, Martína; Godoy-Ortiz, Ana; Queipo-Ortuño, María Isabel; Vicioso-Recio, Luis Prudencio; Díaz-Córdoba, Gema; Roldán-Díaz, María Dunia; Velasco-Suelto, Jesús; Hernando Melia, Cristina; Bermejo, Begoña; Julve-Parreño, Ana; Lluch, Ana; Pascual, Javier; Comino-Méndez, Iñaki; Alba-Conejo, Emilio[et al.] (IOAP-MDPI, 2022-12-21)
Breast cancer (BC) is the most prevalent cancer in women. While usually detected when localized, invasive procedures are still required for diagnosis. Herein, we developed a novel ultrasensitive pipeline to detect circulating ... -
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HRþ)/HER2-negative advanced breast cancer patients.
Ribelles, Nuria; Jerez-Aragonés, José Manuel; Rodríguez-Brazzarola, Pablo; Jiménez-Rodríguez, Begoña; Díaz-Redondo, Tamara; Mesa, Héctor; Márquez, Antonia; Sánchez-Muñoz, Alfonso; Pajares, Bella; Carabantes, Francisco; Bermejo-Pérez, María José; Villar, Ester; Domínguez-Recio, María Emilia; Saez-Lara, Enrique; Gálvez Carvajal, Laura; Godoy-Ortiz, Ana; Franco, Leónardo; Ruiz-Medina, Sofía; López, Irene; Alba-Conejo, Emilio[et al.] (Elsevier, 2021)
Background: CDK4/6 inhibitors plus endocrine therapies are the current standard of care in the first-line treatment of HRþ/HER2-negative metastatic breast cancer, but there are no well-established clinical or molecular ...